Phase 4CompletedINTERVENTIONAL
Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients
ClinicalTrials.gov · NCT01761318 · Registry updated: 2016-05-05
- Condition / research focus
- Diabetes Mellitus Type 2; Metabolic Syndrome; Cardiovascular Disease; Diastolic Dysfunction; Fatty Liver
- Sponsor
- Leiden University Medical Center
- Countries with listed sites
- Netherlands
- Registry dates and results
- Start: 2013-11. Completion: 2016-03 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Liraglutide (drug) — also listed as: Trade name: Victoza, EV Product Code: SUB25238, Name of the Marketing Authorisation Holder: Novo Nordisk, Marketing Authorisation number: EU/1/09/529/001, ATC code: A10BX07, CAS number 204656-20-2
- Liraglutide - Placebo (drug) — also listed as: Placebo
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.